AML: The Next Question

For younger patients, of whom 45-50% are cured by chemotherapy, it is likely that chemotherapy will remain as the core of treatment for the foreseeable future. Hopefully efforts will still be made to refine chemotherapy and move beyond the “3+7” approach. The several new none-chemotherapy agents are likely to be added to the chemotherapy backbone. There is a tactical challenge in older patients where it could be argued that the chemotherapy backbone is much less successful. Here, and in older patients who have objective evidence o f prohibitive co-morbidity, more dramatic changes are justifiable such as up-front transplant or epigenetic therapy as the backbone of the new combinations such as with venetoclax.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alan K. Burnett Source Type: research